The Antitumor Effect of Compound Mylabris on Hepatocellular Carcinoma
|School||Guangdong College of Pharmacy|
|Keywords||compound mylabris p53 c-Myc Serum pharmacology H22 hepatoma ascites bearing mouse model|
Objective To investigate the antitumor effect of compound mylabris on the hepatocellular carcinoma and its possible mechanism.Methods The compound mylabris serum was prepared based on serum pharmacology and was used to treat human hepatocarcinoma cell line bel-7402. Different concentrations of compound mylabris serum were used to treat bel-7402 cell for 24 h, 48 h, 78 h, and their inhibitory effect were detected by MTT assay. RT-polymerase chain reaction (RT-PCR) was used to evaluate c-Myc and p53 mRNA expressions in human Hepatocarcinoma cell bel-7402. Flow cytometry was used to detect the effect of compound mylabris serum on cell cycle of bel-7402. The H22 hepatoma ascites bearing mouse model was set up, and was used to investigate the effect of the compound mylabris on the life time of the model mouse.Results Compound mylabris serum could inhibit remarkably the proliferation of human hepatocarcinoma cell line bel-7402. The MTT results showed that inhibitory effect of compound mylabris serum on bel-7402 was time and concentration dependent. The inhibitory rates of the groups of low, middle and high concentration for 24 hours were 6%, 12%, 13%, respectively; while for the groups of 48 hours and 72 hours, they were 13%, 15%, 27% and 15%, 32%, 32%, respectively. In comparison with the control group, the groups of compound mylabris serum showed significant inhibitory effect (p < 0.05). The results of RT–PCR showed that the compound mylabris can downregulate c-Myc gene, while upregulate p53 gene. The flow cytometry showed that cell cycles of bel-7402 were blocked into the G2M phase after being treated by compound mylabris serum with middle and high concentration for 24, 48 and 72 hours (p < 0.05). The compound mylabris can not significantly lengthen the life span of H22 hepatoma ascites bearing mouse model, but it can remarkably improve their life quality, such as hair color, moving ability and sensitivity to the environment.Conclusion Compound mylabris can inhibit the proliferation of human hepatocarcinoma cell. This may be achieved by affecting the expressions of P53 and c-Myc gene, and thereby blocking the cell cycle into the G2M phase. Compound mylabris may improve the immunocompetence of the tumor bearing mouse and thus better its life quality. Serum pharmacology in combination with molecular biology can effectively disclose target molecules reacting with the drug, and therefore can be used as a preliminary technology platform for compound pharmacology.